The invention concerns TGF- beta in a crystalline form which shows no adsorption or less adsorption to the wall of vials than the soluted TGF- beta and which is more stable towards oxidative agent tahn the soluted form. TGF- beta crystals of the invention can be used for structure determination and for drug design and for the production of a slow release pharmaceutical preparation.
